Haematology 2018

Double Expressers

• Not recognised as a distinct entity. Biomarker for poor response • Different IHC thresholds • No prospective trials • Priority for clinical investigations with novel agents • At present R-CHOP

1.0

Other (n=236) MYC + /BCL2 + (n=55) DHIT (n=14)

0.8

0.6

0.4

0.2

P < .001 * P = 0.14 (MYC + /BCL2 + v other)

Overall Survival (Proportion)

0.0

0

3

5

8

10

OS (years)

Johnson N A et al. JCO 2012;30:3452-3459